10-Q: GeneDx Reports Strong Q3 Growth, Acquires Fabric Genomics

GeneDx Holdings Corp. reported significant revenue growth and reduced net losses for the third quarter and first nine months of 2025, driven by increased diagnostic test volumes and the acquisition of Fabric Genomics.

Summary

• Total revenue for the three months ended September 30, 2025, increased by 52% to $116.7 million, up from $76.9 million in the prior year.
• Diagnostic test revenue grew 47% to $113.5 million for the quarter, primarily due to a 65% increase in whole exome and genome sequencing revenues.
• Whole exome and genome test volumes increased by 33% for the quarter and 29% for the nine months ended September 30, 2025.
• Gross profit for the quarter surged 77% to $84.5 million, with gross margin improving to 72.4% from 62.2% year-over-year.
• Net loss for the three months ended September 30, 2025, improved by 8% to $7.6 million, compared to $8.3 million in the same period last year.
• For the nine months ended September 30, 2025, total revenue increased 46% to $306.6 million, and net loss significantly improved by 94% to $3.4 million from $57.7 million in the prior year.
• The company acquired Fabric Genomics on May 5, 2025, for approximately $33.5 million in cash, which contributed $2.0 million in revenue for the quarter and $2.9 million for the nine-month period.
• Cash and cash equivalents stood at $96.0 million, and marketable securities at $59.1 million as of September 30, 2025.

Sentiment

Score: 8

Explanation: The company demonstrated strong financial performance with significant revenue growth, improved gross margins, and a substantial reduction in net loss, indicating a positive trajectory towards profitability. The acquisition of Fabric Genomics and FDA Breakthrough Device Designation are strategic positives, despite increased operating expenses and ongoing legal matters.

Positives

• Strong revenue growth of 52% for the three months and 46% for the nine months ended September 30, 2025.
• Significant improvement in gross profit, up 77% for the three months and 67% for the nine months, driven by higher test volumes and improved reimbursement rates.
• Net loss substantially reduced by 8% for the three months and 94% for the nine months ended September 30, 2025, indicating a positive trajectory towards profitability.
• Positive net cash provided by operating activities of $36.4 million for the nine months ended September 30, 2025, a significant turnaround from a net cash outflow in the prior year.
• Successful acquisition of Fabric Genomics, expanding AI-based Next Generation Sequencing analysis capabilities.
• Received FDA Breakthrough Device Designation in October 2025 for ExomeDx™ and GenomeDx™ tests, potentially accelerating future review and authorization.

Negatives

• Increased operating expenses across research and development (70% for Q3), selling and marketing (38% for Q3), and general and administrative (65% for Q3) due to expansion and acquisition costs.
• A loss of $2.5 million for the change in fair value of contingent consideration related to the Fabric Genomics acquisition for the three months ended September 30, 2025.
• Ongoing legal proceedings, including a securities class action lawsuit where the motion to dismiss was denied, and multiple derivative suits.
• Third-party payor reserves increased to $21.3 million as of September 30, 2025, including $12.0 million in scheduled payments for disputed claims.

Risks

• Unforeseen circumstances or disruptions from general economic and political conditions, including recessions, fluctuating inflation, interest rates, supply chain interruptions, and public health emergencies.
• Ability to successfully implement new strategic directions and realize cost savings from exiting reproductive, women's, and somatic tumor testing businesses.
• Ability to realize the expected benefits of the Fabric Genomics acquisition.
• Risks related to governmental regulation and other legal obligations, including privacy, data protection, information security, consumer protection, and anti-corruption and anti-bribery.
• Ability to obtain and maintain intellectual property protection for product candidates.
• Ability to compete against existing and emerging technologies.
• Third-party payor reimbursement and coverage decisions, negotiations, and settlements.
• Reliance on third-party service providers for data programs.
• Volatility of stock price.
• Ability to attract and retain key personnel.
• Changes in FDA oversight for laboratory developed tests (LDTs) could subject operations to much more significant regulatory requirements, despite a recent court ruling striking down the 2024 FDA final rule.
• A Breakthrough Device Designation by the FDA, even if granted, may not lead to faster development, regulatory review or authorization, nor does it increase the likelihood that any product candidates will receive regulatory authorization.
• Prohibitions against the corporate practice of medicine in various states may result in civil or criminal fines, as well as sanctions.
• Compliance with growing global privacy and data protection laws, such as the EU's General Data Protection Regulation (GDPR) and UK Data Protection Act 2018 (UK GDPR), may result in significant administrative fines and restrictions on business operations for non-compliance.

Future Outlook

The company expects to continue increasing diagnostic testing volume and services, aiming for long-term cost per test reduction through efficiencies gained from improved laboratory capacity, automation, and value engineering initiatives. Research and development expenses are expected to generally increase in absolute dollars as platforms are expanded, but decrease as a percentage of revenue in the long term. Selling and marketing expenses are also expected to increase in absolute dollars with commercial team expansion and marketing activities, but decrease as a percentage of revenue long-term. General and administrative expenses are anticipated to increase in absolute dollars due to public company operating costs but decrease as a percentage of revenue long-term. The company believes its existing cash and cash equivalents and available-for-sale marketable securities provide sufficient liquidity for at least twelve months from the filing date.

Management Comments

• "We believe that everyone deserves personalized, targeted medical care—and that it all begins with a genetic diagnosis."
• "Fueled by one of the world’s largest rare disease data sets, our industry-leading exome and genome tests translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies."
• "We operate with conviction that what is best for patients must be embedded in every aspect of our work. In support of these beliefs, we value equitability, simplicity and transparency."
• "We expect to continue to focus our resources on increasing the adoption of, and expanding coverage and reimbursement for, our current and any future tests we may develop or acquire."
• "Reducing the costs associated with performing our diagnostic tests is both our focus and a strategic objective."
• "Our performance depends on our ability to retain and broaden the adoption of our services with existing customers as well as our ability to attract new customers."
• "We are seeking to leverage and deploy our platforms to develop a pipeline of future disease-specific research and diagnostic and therapeutic products and services."
• "We expect these designations [FDA Breakthrough Device Designation] to help us accelerate the future review and potential authorization of our exome and genomes tests."

Industry Context

The genomics and diagnostic testing industry is rapidly evolving, with increasing adoption of whole genome sequencing and AI-enabled interpretation in clinical workflows. GeneDx's acquisition of Fabric Genomics and its focus on AI-based platforms align with this trend, aiming for improved accuracy and scalability in rare disease, hereditary risk, and cancer testing. The regulatory landscape for Laboratory Developed Tests (LDTs) remains dynamic, with recent court rulings impacting FDA oversight, creating both uncertainty and potential for new legislative frameworks like the VALID Act. The company's Breakthrough Device Designation for its ExomeDx™ and GenomeDx™ tests positions it to potentially benefit from expedited regulatory pathways, reflecting a broader industry push for faster access to innovative diagnostic tools for life-threatening conditions.

Comparison to Industry Standards

• The filing does not provide specific comparisons to named comparable companies, projects, or results within the industry.

Management Changes

Corporate Governance

Legal Proceedings

• A putative securities class action lawsuit, Helo v. Sema4 Holdings Corp., et al., was filed on September 7, 2022, alleging false and misleading statements about the Centrellis platform. The company's motion to dismiss the second amended complaint was denied on June 23, 2025, and discovery is underway.
• Three stockholder derivative suits (Ghazaleh v. Schadt, et al., Scinto v. Schadt, et al., and Ingrao v. Ryan, et al.) have been filed, largely based on similar allegations as the securities class action. These suits are currently stayed pending the resolution or settlement announcement of the Helo class action.

Related Party Transactions

• The company incurred $1.9 million in purchases of diagnostic testing kits and lab materials from Twist Biosciences (Twist) for the three months ended September 30, 2025, and $6.1 million for the nine months ended September 30, 2025.
• Payables due to Twist as of September 30, 2025, were $0.2 million.

Stakeholder Impact

• Shareholders: Positive impact from strong revenue growth, reduced net losses, and strategic acquisition. Potential dilution from future capital raises and stock-based compensation. Ongoing legal proceedings pose a risk.
• Employees: Increased compensation costs reflect investment in product development and commercial teams. Stock-based compensation and ESPP provide incentives.
• Customers (Patients/Healthcare Professionals): Increased test volumes and improved reimbursement rates suggest growing adoption and access to diagnostic services. Acquisition of Fabric Genomics aims to enhance AI-based analysis.
• Suppliers: Continued reliance on a limited number of suppliers for certain reagents and lab materials, managed by maintaining surplus stock and availability of alternative suppliers.
• Regulatory Bodies: Compliance with SEC filing requirements. Engagement with FDA through Breakthrough Device Designation. Monitoring evolving LDT regulations.

Next Steps

• Finalize fair values of assets acquired, contingent consideration, and liabilities assumed for the Fabric Genomics acquisition within one year of the Merger Date (May 5, 2025).
• Continue to evaluate the full impact of the One Big Beautiful Bill Act (OBBBA) changes as additional guidance becomes available.
• Cease to qualify as an emerging growth company as of December 31, 2025, and comply with associated reporting requirements.
• Make scheduled payments of $10.0 million by December 31, 2025, and $2.0 million by June 2026 for third-party payor disputed claims.
• Continue discovery in the Helo v. Sema4 Holdings Corp., et al. securities class action lawsuit.
• Monitor and ensure compliance with any changes to Laboratory Developed Test (LDT) regulatory policy.
• Accelerate future review and potential authorization of ExomeDx™ and GenomeDx™ tests following FDA Breakthrough Device Designation.
• File a new automatic shelf registration statement with the SEC to replace the expired one.
• Potentially seek additional funding through equity, debt, or other third-party funding.

Key Dates

Recommendation

GeneDx Holdings Corp. demonstrates strong operational momentum with significant revenue growth (52% for Q3, 46% YTD) driven by increased diagnostic test volumes and improved reimbursement rates for high-value exome and genome sequencing. The substantial reduction in net loss (94% YTD) and positive cash flow from operations ($36.4M YTD) indicate a clear path towards profitability and improved financial health. The strategic acquisition of Fabric Genomics enhances AI-based diagnostic capabilities, and the FDA Breakthrough Device Designation for key tests provides a competitive advantage and potential for accelerated market access. While increased operating expenses and ongoing legal proceedings warrant monitoring, the overall trajectory and strategic advancements suggest a compelling investment opportunity for long-term growth in the genomics and precision medicine sector.

Keywords

Genomics, Diagnostic Testing, Rare Disease, Exome Sequencing, Genome Sequencing, AI Platform, Fabric Genomics, Biopharma, Healthcare Technology, SEC Filing, Financial Results, FDA Breakthrough Device, Precision Medicine